| Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) (NCT00633542) | Università Politecnica delle Marche | 2003-06-01 |
| Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure (NCT00062621) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-06-01 |
| Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) (NCT00215943) | H. Lee Moffitt Cancer Center and Research Institute | 2003-06-01 |
| Phase I Study of Sequential Cord Blood Transplants (NCT00299767) | Massachusetts General Hospital | 2003-05-01 |
| Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) (NCT00060645) | Merck Sharp & Dohme LLC | 2003-05-01 |
| The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma (NCT00207805) | Centre National de Greffe de Moelle Osseuse | 2003-05-01 |
| An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma (NCT02182141) | Boehringer Ingelheim | 2003-04-01 |
| A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma (NCT00622336) | Celgene | 2003-04-01 |
| Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) (NCT00060632) | Merck Sharp & Dohme LLC | 2003-04-01 |
| Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells (NCT00186316) | Stanford University | 2003-04-01 |
| Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant (NCT00143845) | University of Michigan Rogel Cancer Center | 2003-04-01 |
| A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies (NCT00621244) | Novartis Pharmaceuticals | 2003-03-01 |
| A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) (NCT00091624) | Celgene Corporation | 2003-03-01 |
| FREE Study - Fracture Reduction Evaluation (NCT00211211) | Medtronic Spine LLC | 2003-02-01 |
| Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF (NCT00952237) | Dartmouth-Hitchcock Medical Center | 2003-01-01 |
| CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma (NCT00056160) | Celgene | 2003-01-01 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders (NCT00533923) | Beth Israel Deaconess Medical Center | 2002-12-01 |
| Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma (NCT00327314) | Azienda Ospedaliera San Giovanni Battista | 2002-12-01 |
| Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer (NCT00053196) | Alliance for Clinical Trials in Oncology | 2002-12-01 |
| A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life (NCT00222105) | University of Kansas Medical Center | 2002-11-01 |
| Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies (NCT00113646) | Massachusetts General Hospital | 2002-11-01 |
| Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT (NCT00599495) | Universitätsklinikum Hamburg-Eppendorf | 2002-11-01 |
| Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT (NCT00516152) | University of California, San Francisco | 2002-11-01 |
| Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer (NCT00047788) | Genzyme, a Sanofi Company | 2002-10-01 |
| T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant (NCT00048464) | Xcyte Therapies | 2002-10-01 |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies (NCT00514722) | University of California, San Francisco | 2002-10-01 |
| UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma (NCT00580372) | University of Arkansas | 2002-08-01 |
| Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma (NCT00124813) | University Hospital, Bonn | 2002-08-01 |
| A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. (NCT00300664) | Royal Marsden NHS Foundation Trust | 2002-07-01 |
| PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (NCT00048230) | Millennium Pharmaceuticals, Inc. | 2002-06-01 |
| S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT00040937) | SWOG Cancer Research Network | 2002-06-01 |
| Assessing Free Immunoglobulin Light Chains in Patients With Myeloma (NCT00301275) | Royal Marsden NHS Foundation Trust | 2002-06-01 |
| S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma (NCT00900263) | SWOG Cancer Research Network | 2002-06-01 |
| A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 (NCT00063726) | Millennium Pharmaceuticals, Inc. | 2002-04-01 |
| CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma (NCT00044018) | Celgene | 2002-04-01 |
| Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy (NCT00303719) | Masonic Cancer Center, University of Minnesota | 2002-03-26 |
| THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) (NCT01341262) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2002-03-01 |
| Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma (NCT00193544) | SCRI Development Innovations, LLC | 2002-03-01 |
| A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma (NCT00039754) | Poniard Pharmaceuticals | 2002-03-01 |
| Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma (NCT00988312) | University Hospital Carl Gustav Carus | 2002-03-01 |
| FM 140 vs FM100 Study in Patients With Multiple Myeloma (NCT00505895) | M.D. Anderson Cancer Center | 2002-01-01 |
| Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients (NCT00232934) | Gruppo Italiano per lo Studio del Mieloma Multiplo | 2002-01-01 |
| Thalidomide to Patients With Previously Untreated Multiple Myeloma (NCT00218855) | Norwegian University of Science and Technology | 2002-01-01 |
| Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma (NCT00657488) | Celgene | 2001-12-01 |
| Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. (NCT00325416) | H. Lee Moffitt Cancer Center and Research Institute | 2001-11-19 |
| Genome Expression in Lymphoma, Leukemia and Multiple Myeloma (NCT00339963) | National Cancer Institute (NCI) | 2001-11-09 |
| Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions (NCT00029224) | Novartis | 2001-10-01 |
| Stem Cell Transplant for Hematological Malignancy (NCT00176930) | Masonic Cancer Center, University of Minnesota | 2001-10-01 |
| Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia (NCT00513175) | University of California, San Francisco | 2001-10-01 |
| Effects of Exercise in Combination With Epoetin Alfa (NCT00577096) | University of Arkansas | 2001-10-01 |
| Nonmyeloablative Allogeneic Transplant (NCT01272817) | Scripps Health | 2001-10-01 |
| Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years (NCT00546988) | University of Wuerzburg | 2001-10-01 |
| Blood and Marrow Transplant Clinical Research Network (NCT00023530) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-09-01 |
| Stem Cell Translpantation in Multiple Myeloma (NCT05082675) | European Society for Blood and Marrow Transplantation | 2001-09-01 |
| Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD) (NCT00854139) | Massachusetts General Hospital | 2001-08-01 |
| Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy (NCT00205751) | Austrian Forum Against Cancer | 2001-08-01 |
| 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis (NCT00075608) | Boston Medical Center | 2001-08-01 |
| Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy (NCT02288741) | WiSP Wissenschaftlicher Service Pharma GmbH | 2001-08-01 |
| Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma (NCT00772811) | Cooperative Study Group A for Hematology | 2001-07-01 |
| Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies (NCT00050687) | Titan Pharmaceuticals | 2001-06-01 |
| DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation (NCT00083915) | University of Arkansas | 2001-06-01 |
| The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen (NCT01890486) | Wake Forest University Health Sciences | 2001-05-21 |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation (NCT00038818) | M.D. Anderson Cancer Center | 2001-05-01 |
| Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma (NCT00024466) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2001-04-01 |
| A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma (NCT00323505) | Royal Marsden NHS Foundation Trust | 2001-03-01 |
| Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma (NCT00006184) | National Cancer Institute (NCI) | 2001-02-08 |
| Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally (NCT00083538) | University of Arkansas | 2001-02-01 |
| Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma (NCT00012350) | H. Lee Moffitt Cancer Center and Research Institute | 2001-01-01 |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant (NCT00571662) | University of Nebraska | 2000-12-08 |
| Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) (NCT00732641) | Merck Sharp & Dohme LLC | 2000-12-01 |
| Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma (NCT00116441) | Cell Genesys | 2000-10-01 |
| Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma (NCT00185653) | Stanford University | 2000-10-01 |
| Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NCT00344422) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2000-10-01 |
| Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma (NCT00185614) | Wen-Kai Weng | 2000-08-01 |
| Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis (NCT00075621) | Boston Medical Center | 2000-08-01 |
| Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders (NCT00582621) | Memorial Sloan Kettering Cancer Center | 2000-07-01 |
| Thalidomide-Dexamethasone for Multiple Myeloma (NCT00038090) | M.D. Anderson Cancer Center | 2000-06-01 |
| Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H (NCT00048412) | Baylor College of Medicine | 2000-06-01 |
| Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma (NCT00367185) | University Hospital, Lille | 2000-05-01 |
| Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma (NCT00781170) | Universitätsklinikum Hamburg-Eppendorf | 2000-05-01 |
| S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma (NCT00005834) | SWOG Cancer Research Network | 2000-04-01 |
| IFM 99-02 Thalidomide in Myeloma (NCT00222053) | University Hospital, Toulouse | 2000-04-01 |
| Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood (NCT00143884) | University of Michigan Rogel Cancer Center | 2000-03-01 |
| Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (NCT01499147) | University of Illinois at Chicago | 2000-02-01 |
| Collection of Samples and Clinical Data From Patients With Amyloid Diseases (NCT00898235) | Boston Medical Center | 2000-01-01 |
| Pethema Multiple Myeloma 2000 (NCT00560053) | PETHEMA Foundation | 2000-01-01 |
| Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month (NCT00376883) | Nordic Myeloma Study Group | 2000-01-01 |
| Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia (NCT00037791) | Pfizer | 1999-12-01 |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants (NCT00001830) | National Cancer Institute (NCI) | 1999-07-20 |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders (NCT00636909) | Beth Israel Deaconess Medical Center | 1999-07-01 |
| Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi) (NCT00702247) | Azienda Ospedaliera San Giovanni Battista | 1999-07-01 |
| Thalidomide for Multiple Myeloma (NCT00038233) | M.D. Anderson Cancer Center | 1999-05-01 |
| Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy (NCT00205764) | Austrian Forum Against Cancer | 1999-03-01 |
| Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant (NCT00530218) | City of Hope Medical Center | 1999-03-01 |
| The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers (NCT00001873) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-02-22 |
| D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma (NCT00083876) | University of Arkansas | 1998-09-01 |
| An Open Protocol for the Compassionate Use of Thalidomide (NCT00081757) | University of Arkansas | 1998-09-01 |
| Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma (NCT00120263) | London Health Sciences Centre | 1998-09-01 |
| Comparing Treatments for Multiple Myeloma (NCT00001750) | National Heart, Lung, and Blood Institute (NHLBI) | 1998-09-01 |
| UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy (NCT00083551) | University of Arkansas | 1998-08-01 |